Intellia Therapeutics (NTLA) Common Equity (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Common Equity data on file, last reported at $620.9 million in Q1 2026.

• Quarterly Common Equity fell 20.38% year-over-year to $620.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $620.9 million (down 20.38% YoY) and the FY2025 annual result came in at $671.4 million, down 23.0% from the prior year.
• Common Equity retreated to $620.9 million in Q1 2026 per NTLA's latest filing, from $671.4 million in the prior quarter.
• Across five years, Common Equity topped out at $1.2 billion in Q4 2022 and bottomed at $620.9 million in Q1 2026.
• The 5-year median for Common Equity is $953.8 million (2022), against an average of $920.9 million.
• The widest annual swing landed in 2022, when Common Equity soared 77.96%; it then declined 26.34% in 2025.
• Tracing NTLA's Common Equity over 5 years: stood at $1.2 billion in 2022, then slipped by 15.01% to $1.1 billion in 2023, then retreated by 16.97% to $872.0 million in 2024, then declined by 23.0% to $671.4 million in 2025, then decreased by 7.51% to $620.9 million in 2026.
• Per Business Quant, the three latest NTLA Common Equity figures stand at $620.9 million (Q1 2026), $671.4 million (Q4 2025), and $748.4 million (Q3 2025).

Peer Comparison